Table 1.
Clinical features of cohort.
| Full Cohort | Incident User Cohort | Established User Cohort | |||||||
|---|---|---|---|---|---|---|---|---|---|
| MPR<80% (n=71) | MPR ≥80% (n=384) | p-value | MPR<80% (n=17) | MPR ≥80% (n=68) | p-value | MPR<80% (n=54) | MPR ≥80% (n=316) | p-value | |
| Demographics at time of VARA enrollment | |||||||||
| Age at enrollment, years mean(SD) | 62 (12) | 64 (11) | 0.17 | 63 (12) | 62 (12) | 0.64 | 62 (12) | 65 (11) | 0.08 |
| Disease duration, years | 9.4 (10.3) | 9.4 (11.7) | 0.94 | 6.5(7.5) | 9.4 (12) | 0.5 | 10.2 (11) | 9.5 (128) | 0.66 |
| Male n (%) | 63 (89%) | 355 (92%) | 0.37 | 14 (83%) | 66 (97%) | 0.02 | 49 (91%) | 289(91%) | 0.86 |
| Race/ethnicity | |||||||||
| Caucasian | 51 (72%) | 316 (83%) | 0.05 | 11 (65%) | 58 (85%) | 0.05 | 40 (74%) | 258 (82%) | 0.19 |
| African-American | 18 (25%) | 49 (13%) | 0.01 | 5 (29%) | 9 (13%) | 0.11 | 13 (24%) | 40 (13%) | 0.03 |
| Hispanic | 1 (1%) | 11 (1%) | 0.44 | 1 (6%) | 1 (1%) | 0.50 | 0 | 10 (3%) | 0.18 |
| Other/not specified | 1 (1%) | 8 (2%) | 0.44 | 0 | 0 | - | 1 (2%) | 8 (3%) | 0.35 |
| Ever tobacco user n (%) | 50 (70%) | 300 (78%) | 0.07 | 12 (71%) | 60 (88%) | 0.07 | 40 (74%) | 236 (75%) | 0.38 |
| Enrollment clinical measures- Mean (S.D.) | |||||||||
| DAS28 (0–28) | 4.4 (1.8) | 3.8 (1.6) | 0.02 | 4.9 (1.6) | 4.6 (1.7) | 0.45 | 4.2 (1.8) | 3.7 (1.5) | 0.03 |
| Tender joints (0–28) | 7.1 (8.0) | 5.0 (6.7) | 0.02 | 7.4 (7.6) | 7.6 (8.0) | 0.90 | 7.0 (8.2) | 4.7 (6.3) | <0.01 |
| Swollen joints (0–28) | 6.7 (7.4) | 4.2 (5.4) | <0.01 | 9.0 (7.6) | 6.2 (6.3) | 0.12 | 6.0 (7.8) | 3.8 (5.2) | <0.01 |
| MDHAQ (0–3.0) | 0.9 (0.7) | 0.9 (0.6) | 0.98 | 1.0 (0.7) | 1.0 (0.5) | 0.79 | 0.9 (0.7) | 0.9 (0.6) | 0.99 |
| Pain (0–10) | 4.7 (3.2) | 4.4 (2.8) | 0.42 | 4.6 (3.3) | 4.5 (2.8) | 0.90 | 4.7 (3.2) | 4.3 (2.8) | 0.41 |
| Patient global (0–100) | 41 (29) | 40 (26) | 0.88 | 46 (20) | 46 (26) | 0.99 | 34 (24) | 35 (22) | 0.76 |
| ESR, mm/hr | 32 (27) | 24 (21) | 0.02 | 36 (24) | 27.1 (21) | 0.15 | 30.3 (28.1) | 24.5 (21.5) | 0.04 |
| Rheumatoid factor positive | 61 (86%) | 298 (78%) | 0.13 | 12 (715%) | 55 (81%) | 0.35 | 49 (91%) | 243 (77%) | 0.02 |
| aCCP positive | 53 (75%) | 290 (76%) | 0.85 | 13 (76%) | 54 (79%) | 0.97 | 04 (74%) | 236 (75%) | 0.90 |
| Deyo Index | 1.6 (2.1) | 1.5 (1.8) | 0.67 | 1.8 (1.7) | 1.2 (1.6) | 0.20 | 1.6 (2.2) | 1.6 (1.8) | 0.94 |
| Concurrent therapy with MTX – n (%) | |||||||||
| Traditional DMARDs † | 39 (55%) | 226 (59%) | 0.54 | 7 (41%) | 33 (49%) | 0.59 | 32 (59%) | 193 (61%) | 0.80 |
| TNF alpha blockers ‡ | 29 (41%) | 143 (37%) | 0.56 | 7 (41%) | 12 (18%) | 0.04 | 22 (41%) | 131 (41%) | 0.92 |
| Other Biologic DMARSs # | 1 (1%) | 12 (3%) | 0.43 | 1 (6%) | 0 (0%) | 0.00 | 0 (0%) | 12 (4%) | 0.16 |
†
Traditional DMARDs included auranofin, azathioprine, cyclosporine, injectable gold, hydroxychloroquine, leflunomide, minocycline, sulfasalazine.
‡
TNF blockers included adalimumab, etanercept, and infliximab
#
Other Biologic agents were abatacept and rituximab
*
= P <0.05 and marked in bold